Placebo-controlled study of montelukast and budesonide on short-term growth in prepubertal asthmatic children.
Pediatr Pulmonol
; 42(9): 838-43, 2007 Sep.
Article
en En
| MEDLINE
| ID: mdl-17659605
ABSTRACT
BACKGROUND:
Inhaled corticosteroids and anti-leukotriene agents are widely used in the treatment of pediatric asthma. Although data on the effect of corticosteroids on growth are available, there are few such data on anti-leukotriene agents. The aim of this study was to assess the influence of montelukast on short-term lower leg growth rate (LLGR) in prepubertal children with asthma.METHODS:
Forty-two boys (6- to 12-year old) and 29 girls (6- to 11-year old) with mild asthma were randomized to 1 of 2 crossover arms, with two treatment sequences per arm montelukast 5 mg once daily/placebo or inhaled dry powder budesonide 200 microg twice daily/placebo. Budesonide was used as a positive control to ensure that the method was sensitive enough to detect a suppression of LLGR. The 3-week double-blind treatment period was followed by a 3-week washout. Primary outcome was LLGR over the 3-week treatment, measured by knemometry.RESULTS:
Ninety-four percent of patients completed the study. Mean LLGR was similar between patients receiving montelukast and placebo treatments mean difference, -0.02 mm/week [95% confidence interval -0.14, 0.11]. Mean LLGR in patients receiving budesonide was significantly less than for those receiving placebo (difference of -0.16 mm/week [-0.25, -0.06], P = 0.002). Mean LLGR was similar for patients taking placebo in the two arms (0.43 and 0.44 mm/week).CONCLUSION:
Montelukast 5 mg did not significantly affect short-term LLGR in prepubertal children.
Buscar en Google
Base de datos:
MEDLINE
Asunto principal:
Quinolinas
/
Asma
/
Estatura
/
Antiasmáticos
/
Budesonida
/
Pierna
/
Acetatos
Tipo de estudio:
Clinical_trials
Idioma:
En
Revista:
Pediatr Pulmonol
Asunto de la revista:
PEDIATRIA
Año:
2007
Tipo del documento:
Article